KTTA

Market Overview: U.S. stocks experienced significant declines, with the Dow Jones dropping over 4%, while initial jobless claims rose to 223,000. In contrast, European and Asian markets saw gains, with notable increases in major indices.

Sector Performance: Consumer staples shares increased by 0.9%, while energy shares fell by 5%. Several healthcare stocks surged due to positive developments, while companies like Marin Software and Venus Concept faced steep declines following negative announcements.

U.S. Stock Market Performance: U.S. stocks fell significantly, with the Dow Jones dropping over 800 points and other indices like NASDAQ and S&P 500 also experiencing declines, while consumer staples saw a slight increase.

Inflation and Economic Indicators: The annual inflation rate in the U.S. decreased to 2.4% in March, marking its lowest level since September, alongside a rise in initial jobless claims by 4,000 to 223,000 for the first week of April.

Clinical Trial Update: Pasithea Therapeutics has received a recommendation from the Safety Review Committee to escalate their Phase 1 clinical trial of PAS-004 to the next dose level of 30mg, as no dose-limiting toxicities or rashes have been observed in previous cohorts.

Company Focus and Future Plans: The company is focused on developing innovative treatments for neurofibromatosis type 1 and other cancer indications, with ongoing evaluations of safety and efficacy expected to be reported in the coming weeks.

Safety Review Committee Recommendation: Pasithea Therapeutics Corp. has received approval from the external Safety Review Committee to proceed with Cohort 6 of its Phase 1 study for PAS-004 in advanced cancer, based on safety data showing no dose limiting toxicities.

Enrollment and Patient Identification: The company reports strong demand for enrollment and has already identified patients for the next cohort, indicating progress in their clinical trial efforts.

Pasithea Therapeutics Presentation: Mathew Lazarus, VP of Pasithea Therapeutics, will present PAS-004, a macrocyclic MEK inhibitor for cancer treatment, at the CAGLA NeauxCancer Conference on March 28, 2025, in New Orleans, sharing interim data from an ongoing Phase 1 study.

Conference Details: The CAGLA NeauxCancer Conference is a prominent event for oncology professionals to discuss advancements in cancer care, scheduled for March 27-29, 2025.

U.S. Stock Market Performance: U.S. stocks showed mixed results with the Dow Jones gaining 0.13%, while NASDAQ and S&P 500 fell by 0.36% and 0.09% respectively; notable movers included Criteo and Aurora Cannabis with significant gains, while Volcon and FMC Corp experienced sharp declines.

Economic Indicators: The U.S. trade deficit widened to $98.4 billion in December, private businesses added 183,000 jobs in January, and the ISM services PMI decreased to 52.8, indicating a slowdown in service sector growth.

Market Performance: U.S. stocks showed mixed results with the Nasdaq Composite down 0.55%, while the Dow rose slightly by 0.08%. Notable movements included a surge in utility shares and significant drops in communication services.

Company Highlights: The Walt Disney Company reported better-than-expected earnings, while several stocks like Oragenics and Aurora Cannabis saw substantial gains. Conversely, Volcon Inc and FMC Corp experienced significant declines following negative announcements.

Clinical Trial Expansion: Pasithea Therapeutics has opened three clinical trial sites in Eastern Europe for its PAS-004 Phase 1 trial, which is aimed at treating neurofibromatosis type 1 and other cancer indications, alongside existing sites in the U.S.

Upcoming Data Presentation: The company plans to present interim safety and pharmacokinetic data from ongoing patient cohorts in Q1 2025, following initial dosing of patients in Cohort 4A and ongoing recruitment for Cohort 4B.

Trial Progress: Pasithea Therapeutics has received a recommendation from the Safety Review Committee to escalate the dosage of PAS-004 to 15mg, with no dose-limiting toxicities or rashes observed in initial patients.

Drug Profile: PAS-004 is a next-generation MEK inhibitor that offers potential advantages over first-generation drugs, including once-daily dosing and prolonged target inhibition, making it a promising candidate for treating neurofibromatosis type 1 and other cancers.

Pasithea Therapeutics Offering: Pasithea Therapeutics Corp. announced a private placement for the sale of 1,219,513 shares of common stock and warrants, aiming to raise approximately $5 million for working capital and corporate purposes, with the closing expected around September 30, 2024.

Company Focus and Future Outlook: The company is developing PAS-004, a macrocyclic MEK inhibitor for neurofibromatosis type 1 and other cancers, while also emphasizing its commitment to innovative treatments for CNS disorders and RASopathies amidst various risks associated with clinical trials and market conditions.

U.S. Stock Market Performance: U.S. stocks saw gains with the Dow Jones rising over 250 points, while Accenture reported better-than-expected earnings and announced a cash dividend increase and share repurchase authority.

Global Economic Indicators: European shares closed higher, Asian markets mostly rose, and U.S. economic data showed mixed results with core PCE prices increasing and jobless claims falling.

U.S. Stock Market Performance: U.S. stocks rose with the Dow Jones gaining around 200 points, while initial jobless claims decreased to 218,000, indicating a stronger labor market than expected.

Global Market Trends: European and Asian markets also saw gains, with significant increases in major indices, while commodity prices showed mixed results, particularly with oil trading down and gold slightly up.

Positive Clinical Trial Results: Pasithea Therapeutics Corp. reported promising initial results from its Phase 1 trial of PAS-004, a macrocyclic MEK inhibitor for neurofibromatosis type 1 and various cancers, leading to a 76% increase in stock price.

Key Findings: The trial demonstrated safety, tolerability, and effectiveness with no treatment-related side effects, a long half-life allowing for less frequent dosing, and evidence of disease stability in a patient with stage 3 colon cancer.

U.S. Stock Market Performance: U.S. stocks rose this morning, with the Nasdaq Composite gaining over 1%, while Micron Technology reported better-than-expected fourth-quarter results, boosting investor sentiment.

Global Market Trends: European and Asian markets also saw gains, with significant increases in major indices, while U.S. economic indicators showed a slight decrease in core PCE prices and a drop in initial jobless claims.

Clinical Trial Results: Pasithea Therapeutics announced positive safety and preliminary efficacy results from its Phase 1 trial of PAS-004 for advanced solid tumors, showing no adverse events and a favorable pharmacokinetic profile with potential for once-daily dosing.

Stock Performance: Following the announcement, Pasithea's stock surged by 71.70% in premarket trading, reflecting strong investor interest and increased trading volume.

Clinical Trials Update: Pasithea Therapeutics has completed long-term chronic toxicity studies for its lead candidate PAS-004, showing a consistent safety profile in both rats and dogs, which supports its ongoing Phase 1 clinical trial for advanced cancer patients.

Future Prospects: The company believes that sustained MAPK pathway suppression from PAS-004 could enhance efficacy while reducing side effects compared to other MEK inhibitors, with plans to share additional data from the clinical study later this quarter.

Appointment of Dr. Rebecca Brown: Pasithea Therapeutics has appointed Dr. Rebecca Brown, an expert in neurofibromatosis type 1 (NF1), to its Scientific Advisory Board to aid in the development of PAS-004, a next-generation MEK inhibitor aimed at treating NF1 and other conditions.

Overview of PAS-004: PAS-004 is designed as a macrocyclic MEK inhibitor with potential advantages over existing treatments, including improved pharmacokinetics, safety profiles, and dosing schedules, having received orphan-drug designation from the FDA for NF1 treatment.

Pasithea Therapeutics Q2 2024 Results: The company reported an earnings per share of -$3.71 and did not generate any revenue for the quarter.

InvestorPlace Earnings Automation: InvestorPlace uses automated data from TradeSmith to quickly report on quarterly earnings, including key metrics like earnings per share and revenue, without human intervention.